Ionis Pharmaceuticals (NASDAQ:IONS) has reported promising results from a pivotal study of its experimental medicine, zilganersen, for the treatment of Alexander disease, a rare and progressive neurological disorder. The study found that a 50 mg dose of zilganersen significantly improved ...